Skip to main content
. Author manuscript; available in PMC: 2014 Jun 4.
Published in final edited form as: Phys Biol. 2013 Jun 4;10(3):035002. doi: 10.1088/1478-3975/10/3/035002

Figure 3. Co-drugging sensitizes cells to TRAIL-mediated apoptosis and reduces variability in timing of cell death.

Figure 3

(a-d) Time of death distributions and percentage of surviving HeLa cells treated with TRAIL alone (50ng/ml in (a,c,d); 10ng/ml in (b)), with TRAIL (50ng/ml) + sorafenib (10μM; (a)); TRAIL (10ng/ml) + paclitaxel (300nM; (b)); TRAIL (50ng/ml) + gefitinib (10μM; (c)); TRAIL (50ng/ml) + ABT-737 (10μM; (d)), or with each drug alone, monitored for 16h by live-cell microscopy. For paclitaxel, cells were pre-treated with the drug for 24h to arrest them in mitosis prior to TRAIL addition at the start of the movie (in the continued presence of paclitaxel). Cells surviving at the end of the movie are plotted to the right of the dotted line. (e-h) Quantitation of death times for dying cells only. Box plots represent the spread of the data; the box spans the IQR, with the median indicated as a line through the box; bars span the range of the data, from the minimum to the maximum death time. 50-100 cells were analyzed for each condition.